Also trades as: ACST.V (TSXV) · $vol 0M
ACST NASDAQ
Acasti Pharma Inc.
1W: +5.5%
1M: -3.5%
3M: +38.4%
1Y: +56.9%
3Y: -62.6%
5Y: -96.7%
$3.37
Last traded 2024-11-22 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$34.2M
52W Range1.98-3.6
Volume27,682
Avg Volume31,697
Beta1.52
Dividend—
Analyst Ratings
Company Info
CEOPrashant Kohli
Employees32
SectorHealthcare
IndustryBiotechnology
IPO Date2012-02-07
Websitegracetx.com
3009 boulevard de la Concorde East
Laval, QC H7E 2B5
CA
Laval, QC H7E 2B5
CA
450 687 2262
About Acasti Pharma Inc.
Acasti Pharma Inc. operates as a biopharmaceutical firm, concentrating its efforts on developing and marketing pharmaceutical solutions specifically for cardiovascular conditions. The company is currently exploring potential strategic alliances to further the clinical development of its drug candidate, CaPre. This Canadian company, which was established in 2002, has its main offices located in Laval.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| ADAR1 Capital Manage | 0 | — | 2024-06-28 | |
| Kumar Amresh | A-Award | 19,740 | $2.96 | 2024-05-06 |
| Macdonald R. Loch | A-Award | 25,380 | $2.96 | 2024-05-06 |
| DelAversano Robert J | A-Award | 4,500 | $2.96 | 2024-05-06 |
| Kohli Prashant | A-Award | 128,770 | $2.96 | 2024-05-06 |